SOST and plasma cell myeloma: Treatment of the myeloma-bearing mice in all three cell lines with an anti-sclerostin antibody caused an increase in osteoblastogenesis, reduced the development of osteolytic lesions and prevented myeloma-induced bone loss whilst increasing bone strength.